艾尔免疫

最新新闻

• 公司公告
  TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL FUND FACTS FR
  SEDAR · 2026/9/29
• 公司公告
  TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL FUND FACTS EN
  SEDAR · 2026/9/29
• ALT Co., Ltd. Calls and Cancels Portion of 7th Convertible Bond Issuance
  TipRanks · 2026/9/14
• 评级变动
  H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Altimmune(ALT.US), With a Forecast Between $10 to $20
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 评级变动
  Truist Financial Maintains Altimmune(ALT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 公司公告
  TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL ETF FACTS EN
  SEDAR · 2026/9/29
• 评级变动
  Leerink Partners Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• 公司公告
  ALT Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major Shareholders
  OPENDART · 2026/10/8
• 评级变动
  Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
  TipRanks · 2026/6/4
• 评级变动
  A Quick Look at Today's Ratings for Altimmune(ALT.US), With a Forecast Between $11 to $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 公司公告
  TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL ETF FACTS FR
  SEDAR · 2026/9/29
• 评级变动
  H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/19
• GLOBAL X INVESTMENTS CANADA INC. BETAPRO -3X NASDAQ-100 DL LEV ALT ETF: INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE FR
  SEDAR · 2026/9/1
• GLOBAL X INVESTMENTS CANADA INC. BETAPRO -3X NASDAQ-100 DL LEV ALT ETF: INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE EN
  SEDAR · 2026/9/1
• 评级变动
  William Blair Maintains Altimmune(ALT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• ALT Co. Executive to Boost Stake With Gifted Shares
  TipRanks · 2026/9/7
• Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/9/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。